Last reviewed · How we verify

Voriconazole high dose

Manjunath Prakash Pai · FDA-approved active Small molecule

Voriconazole high dose is a Triazole antifungal Small molecule drug developed by Manjunath Prakash Pai. It is currently FDA-approved for Invasive aspergillosis, Candidemia and other Candida infections, Esophageal candidiasis. Also known as: Vfend.

Voriconazole inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.

Voriconazole inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane. Used for Invasive aspergillosis, Candidemia and other Candida infections, Esophageal candidiasis.

At a glance

Generic nameVoriconazole high dose
Also known asVfend
SponsorManjunath Prakash Pai
Drug classTriazole antifungal
TargetFungal cytochrome P450 lanosterol 14α-demethylase (CYP51)
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved

Mechanism of action

Voriconazole is a triazole antifungal that selectively targets fungal sterol synthesis by inhibiting the enzyme lanosterol 14α-demethylase (CYP51). This prevents the conversion of lanosterol to ergosterol, a critical component of the fungal cell membrane. The resulting depletion of ergosterol and accumulation of toxic sterol precursors leads to fungal cell membrane instability and cell death. High-dose regimens are used to achieve adequate tissue penetration, particularly in the central nervous system and for treatment of invasive infections.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Voriconazole high dose

What is Voriconazole high dose?

Voriconazole high dose is a Triazole antifungal drug developed by Manjunath Prakash Pai, indicated for Invasive aspergillosis, Candidemia and other Candida infections, Esophageal candidiasis.

How does Voriconazole high dose work?

Voriconazole inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.

What is Voriconazole high dose used for?

Voriconazole high dose is indicated for Invasive aspergillosis, Candidemia and other Candida infections, Esophageal candidiasis, Cryptococcal meningitis, Scedosporium and Fusarium infections.

Who makes Voriconazole high dose?

Voriconazole high dose is developed and marketed by Manjunath Prakash Pai (see full Manjunath Prakash Pai pipeline at /company/manjunath-prakash-pai).

Is Voriconazole high dose also known as anything else?

Voriconazole high dose is also known as Vfend.

What drug class is Voriconazole high dose in?

Voriconazole high dose belongs to the Triazole antifungal class. See all Triazole antifungal drugs at /class/triazole-antifungal.

What development phase is Voriconazole high dose in?

Voriconazole high dose is FDA-approved (marketed).

What are the side effects of Voriconazole high dose?

Common side effects of Voriconazole high dose include Visual disturbances (blurred vision, photopsia), Hepatotoxicity (elevated transaminases), Rash, Photosensitivity, Hallucinations, Hypokalemia.

What does Voriconazole high dose target?

Voriconazole high dose targets Fungal cytochrome P450 lanosterol 14α-demethylase (CYP51) and is a Triazole antifungal.

Related